Comparisons of efficacy and safety of tolterodine and oxybutynin in children with idiopathic overactive bladder

DENG  Yong-Ji; MA  Geng; GUO  Yun-Fei; GE  Zheng; LU  Ru-Gang; WANG  Li-Xia; ZHU  Hao-Bo; CHEN  Chen-Jun

PDF(887 KB)

Chinese Journal of Contemporary Pediatrics ›› 2011, Vol. 13 ›› Issue (1) : 26-28.

CLINICAL RESEARCH

Comparisons of efficacy and safety of tolterodine and oxybutynin in children with idiopathic overactive bladder

DENG Yong-Ji, MA Geng, GUO Yun-Fei, GE Zheng, LU Ru-Gang, WANG Li-Xia, ZHU Hao-Bo, CHEN Chen-Jun

Author information +

History +

Abstract

OBJECTIVE: To compare the efficacy and safety of tolterodine and oxybutynin in the treatment of idiopathic overactive bladder in children. METHODS: A total of 204 children with idiopathic overactive bladder were randomly divided into three groups (n=68 each): placebo, tolterodine-treated and oxybutynin-treated. The efficacy and safety were evaluated two weeks after treatment. RESULTS: The effective rate was 25% in the placebo group, 89% in the tolterodine-treated group, and 92% in the oxybutynin-treated group. The effective rate in the two treatment groups was significantly higher than that in the placebo group (P<0.05). There was a similar efficacy between the two treatment groups. The incidence of adverse events in the tolterodine-treated group (28%) was significantly lower than that in the oxybutnin-treated group (57%) (P<0.05). CONCLUSIONS: Tolterodine has a similar efficacy to oxybutynin in the treatment of idiopathic overactive bladder in children, with better safety in pharmacotherapy.

Key words

Tolterodine / Oxybutynin / Overactive bladder / Child

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

DENG Yong-Ji, MA Geng, GUO Yun-Fei, GE Zheng, LU Ru-Gang, WANG Li-Xia, ZHU Hao-Bo, CHEN Chen-Jun. Comparisons of efficacy and safety of tolterodine and oxybutynin in children with idiopathic overactive bladder[J]. Chinese Journal of Contemporary Pediatrics. 2011, 13(1): 26-28

References

［1］Nevéus T, Von Gontard A, Hoebeke P, Hjalmas K, Bauer S, Bower W, et al. The standardization of terminology of lower urinary tract function in children and adolescents: report from the Standardisation Committee of the International Children′s Continence Society［J］. J Urol, 2006, 176(1): 314-324. ［2］Kajiwara M, Inoue K, Kato M, Usui A, Kurihara M, Usui T. Nocturnal enuresis and overactive bladder in children: an epidemiological study［J］. Int J Urol, 2006, 13(1): 36-41. ［3］Hommaa Y, Yoshidab M, Sekic N, Yokoyamad O, Kakizakie H, Gotohf M, et al. Symptom assessment tool for overactive bladder syndrome--overactive bladder symptom score［J］. Urology, 2006, 68(2): 318-323. ［4］唐达星,孙革. 托特罗定与颠茄合剂治疗儿童逼尿肌过度活跃症疗效比较［J］. 中华小儿外科杂志,2007,28(7):389-390. ［5］Drutz HP, Appell RA, Gleason D, Klimberg I, Radomski S. Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder［J］. Int Urogynecol J Pelvic Floor Dysfunct,1999,10(5): 283-289. ［6］吴士良，崔一民，杨勇，段继宏，那彦群，徐祗顺，等. 酒石酸托特罗定与奥昔布宁双盲双模拟随机对照治疗膀胱过度活动症多中心临床研究［J］. 中国临床药理学杂志,2001,17(5): 337-340. ［7］Nilvebrant L, Andersson KE, Gillberg PG, Stahl M, Sparf B. Tolterodine--a new bladder-selective antimuscarinic agent［J］. Eur J Pharmacol,1997,327(2-3): 195-207. ［8］Raes A, Hoebeke P, Segaert I, Van Laecke E, Dehoorne J, Vande Walle J. Retrospective analysis of efficacy and tolerability of tolterodine in children with overactive bladder［J］. Eur Urol,2004, 45(2): 240-244. ［9］Hjalmas K, Hellstrom AL, Mogren K, Lackgren G, Stenberg A. The overactive bladder in children: a potential future indication for tolterodine［J］. BJU Int, 2001, 87(6): 569-574. ［10］Nijman R, Borgstein NG, Ellsworth P, Djurhuus JC. Tolterodine treatment for children with symptoms of urinary urge incontinence suggestive of detrusor overactivity: results from 2 randomized, placebo controlled trials［J］. J Urol, 2005, 173(4): 1334-1339. ［11］Kilic N, Balkan E, Akgoz S, Sen N, Dogruyol H. Comparison of the effectiveness and side-effects of tolterodine and oxybutynin in children with detrusor instability［J］. Int J Urol, 2006, 13(2): 105-108. ［12］Bolduc S, Upadhyay J, Payton J, Bagli DJ, McLorie GA, Khoury AE, et al. The use of tolterodine in children after oxybutynin failure［J］. BJU Int, 2003, 91(4): 398-401. ［13］Hoebeke P, De Pooter J, De Caestecker K, Raes A, Dehoorne J, Van Laecke E, et al. Solifenacin for Therapy Resistant Overactive Bladder［J］. J Urol, 2009, 182(4): 2040-2044.